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Cancer cells have distinctive nutrient demands to fuel growth and proliferation, including the
disproportionate use of glucose, glutamine, and fatty acids. Comerford et al. and Mashimo et al.
now demonstrate that several types of cancer are avid consumers of acetate, which facilitates
macromolecular biosynthesis and histone modification.Metabolic pathways in cancer cells are
programmed to facilitate survival and pro-
liferation in the nonnative microenviron-
ment of a tumor. This involves changes
in both the way extracellular nutrients
are captured and how they are metabo-
lized. Historically, research efforts have
focused on the wiring of glucose meta-
bolism, owing to the seminal observations
of Warburg and to the dominant role
glucose plays in many basic biosynthetic
processes (Vander Heiden et al., 2009).
The importance of other fuel sources,
including glutamine, lipids, and protein,
have received more recent attention
upon realization that pathways governing
their metabolism are often driven by on-
cogenes. In this issue of Cell, new studies
from the McKnight and Tu (Comerford
et al., 2014) and Maher and Bachoo labs
(Mashimo et al., 2014) illustrate that a
variety of cancers are also capable of
capturing and metabolizing exogenous
acetate and that this represents a meta-
bolic adaptation that some tumors use
to facilitate growth.
Acetate, when ligated to coenzyme A
(acetyl-CoA), is among the most central
and dynamic metabolites in intermediary
metabolism (Figure 1). It can be gener-ated by the oxidation of glucose, gluta-
mine, or fatty acids; it is used to bio-
synthesize nucleotides, amino acids,
and both principle components of the
cell membrane in mammals (i.e., fatty
acids and cholesterol); and it contributes
to enzyme and gene regulation by
reversibly adding to nonhistone protein
and histone tails, respectively (Figure 1)
(Kaelin and McKnight, 2013). Indeed,
numerous studies have illustrated the
fundamental roles that acetyl-CoA regu-
lation plays in cell growth and prolifera-
tive processes (Wellen and Thompson,
2012). However, under oxygen limiting
conditions, as are often seen in the
microenvironment of a tumor, the ability
of a cell to make acetyl-CoA is severely
hampered. Intrigued by this conundrum,
and based on the mechanisms by which
yeast generate acetyl-CoA, Comerford
et al. (2014) explored the functional
relevance of the mammalian homologs
of the yeast enzymes that generate
acetyl-CoA. Mammals express three
isoforms of short-chain acyl-CoA
synthetases (ACSS) that convert acetate
and coenzyme-A into acetyl-CoA by
consuming ATP. Two of these are
localized in mitochondria (ACSS1 andACSS3), and one can access both the
nuclear and cytoplasmic space, ACSS2
(Watkins et al., 2007). Comerford et al.
(2014) find that knockdown of ACSS2,
but not the mitochondrial isoforms,
dramatically impairs the incorporation of
exogenously supplied acetate into lipids
and histone protein. These results illus-
trate that proliferating mammalian cells,
including cancer cells, can consume
and contribute acetate carbon to the
cellular pool of acetyl-CoA.
In a parallel study, Mashimo et al.
(2014) similarly find that exogenous ace-
tate is captured and metabolized, here
by human cancer cells grown in the brain
of mice. The authors examined acetate
metabolism in this context based on an
earlier observation that a significant pro-
portion of carbon in the acetyl-CoA pool
could not be accounted for by tracing
glucose and glutamine metabolism
(Marin-Valencia et al., 2012). By tracing
acetate carbon, Mashimo et al. (2014)
reveal that TCA cycle intermediates
consist of as much as 50% acetate-
derived carbon by mass. In contrast,
non-tumor-bearing brain incorporates
on the order of 10% acetate-derived car-
bon into TCA cycle intermediates. These
Figure 1. Acetyl-CoA Is a Central Node in Carbon Metabolism
Acetyl-CoA plays numerous roles in both regulatory and biosynthetic processes. It can be added in a
posttranslational fashion to histone proteins to regulate gene expression or to other proteins and enzymes
to dictate function or activity. Acetyl-CoA also serves as a principal building block for the generation of
fatty acids, sterols, amino acids, and nucleotides. Acetyl-CoA is primarily generated in the mitochondria
through catabolism of glucose, lipid, and amino acids. Mitochondrial acetyl-CoA is released into the
cytoplasm by citrate export and breakdown. The cytoplasmic acetyl-CoA pool can also be filled by
endogenous and exogenous acetate through reaction with coenzyme A by ACSS2.observations are striking for several
reasons, foremost because it illustrates
that cancer cells are a sink for acetate
and that acetate readily competes with
glucose for generating TCA cycle inter-
mediates, even though glucose is much
more abundant. In these experiments,
in vivo acetate levels are artificially raised
to 0.6 mM, and systemic glucose is
maintained at 5 mM. These results
also provide validation of earlier, provoc-
ative work from the Bachoo and Maher
labs (Marin-Valencia et al., 2012) that
glutamine carbon is not actively oxidized
in the TCA cycle in cells within the brain
microenvironment (both brain cancer
and metastases from other organ dis-
ease). Together, this argues that glucose
and acetate metabolites are the dominant
TCA cycle fuels in these cancers.
The independent but convergent find-
ings from these two teams, which illus-
trate that acetate is readily captured
and metabolized by cancer cells, promp-
ted an exploration of the functional
relevance and necessity of ACSS2 and
acetate metabolism in cancer. To this
end, Comerford et al. (2014) generate
and cross an ACSS2 null mouse into
two models of liver cancer. In both
cases, the tumor burden is significantly
blunted. Consistent with this finding,high ACSS2 protein expression is
observed in a subset of human triple-
negative breast cancer samples, and
this elevation correlates with poor
survival. Similar correlations between
ACSS2 elevation and poor outcome are
obtained by Mashimo et al. (2014) in
low-grade brain tumors (astrocytomas
and oligodendrogliomas).
In both manuscripts, the authors illus-
trate that not only is ACSS2 expressed
in tumors but that it is functional. Comer-
ford et al. (2014) utilize radioactive car-
bon-labeled acetate, [11C]acetate, and
PET imaging. They find that acetate avid-
ity correlates well with ACSS2 expression
in murine tumors. Tumors devoid of
ACSS2 consume much less acetate, and
tumors with high ACSS2 expression are
acetate avid. Mashimo et al. (2014) utilize
nonradioactive [13C]acetate and NMR to
monitor in vivo acetate metabolism in tu-
mors. The advantage of this technique
is that the metabolism of acetate can
be traced into downstream products.
Initially, using orthotopic models with pa-
tient-derived material, they illustrate that
acetate contributes a significant fraction
of carbon to TCA cycle intermediates.
Moreover, they show, using the identical
technique in human patients, that brain
tumors growing in human beings metabo-Cell 159, Delize acetate in a manner nearly identical to
tumors grown orthotopically in the mouse
brain.
Collectively, these results have several
important therapeutic implications. First,
they provide a clear demonstration that
acetate is a metabolic fuel in vivo that
is preferentially utilized by a subset of
cancers. They also illustrate that this is
mediated by ACSS2, whose expression
correlates with tumor aggressiveness in
the six different organ diseases analyzed.
This suggests that acetate avidity and
metabolism may be a general feature
of many cancers. In contrast, normal cells
appear unaffected by loss of ACSS2-
mediated acetate metabolism, as ACSS2
null mice do not exhibit any overt pheno-
typic defects. Taken together, it is reason-
able to conclude that acetate metabolism
may represent an addiction of certain
cancer cells. Furthermore, the results
presented in these studies illustrate the
clinical applicability of two different ace-
tate-measuring technologies—i.e., [11C]
acetate-PET and [13C]acetate-NMR.
Such strategies could be used to identify
patients likely to respond to an antimetab-
olism therapy and could also be used as
markers of therapeutic response.
These findings beg the question as to
how ACSS2 inhibition would affect an
established tumor. The only experiment
presented in this regard revealed that
ACSS2 knockdown by short hairpin
RNA (shRNA) in brain cancer cells grown
in 3D culture resulted in cell death and
an overall reduction in neurospheres.
The astute reader may recognize that,
under such conditions (growth in culture),
very little acetate is present. More to this
point, the concentration of serum acetate
under physiological circumstances is on
the order of 0.2 mM (Tollinger et al.,
1979), raising the question of how a rela-
tively low abundance molecule could
contribute meaningfully to biomass in
a rapidly proliferating cell. To address
this, Comerford et al. (2014) put forth a
persuasive argument for tumor cell evolu-
tion, relating it to that of bacterial cells
evolving in a population, where seemingly
minor advantages can ultimately have
profound impacts. We put forth an addi-
tional, but not mutually exclusive, point
of view based on three pieces of ex-
perimental data from these studies.
First, exogenous acetate, by way ofcember 18, 2014 ª2014 Elsevier Inc. 1493
acetyl-CoA, is found on histone proteins.
Second, ACSS2 is readily observed in the
nucleus of tumor cells, as evidenced by
histological staining. And third, as noted
above, ACSS2 knockdown in human
patient tumor cell lines, grown in media
devoid of acetate, is growth inhibitory.
These finding suggest that the major
role of ACSS2 is to capture acetate
released from deacetylated proteins and
to reincorporate that into the acetyl-CoA
pool for epigenetic regulation. As Comer-
ford et al. (2014) point out, the half-life of
histone acetylation is on the order of mi-
nutes, and a considerable fraction of ac-
etate could be produced in vivo by the
turnover of histone acetylation. ACSS2
in the nucleus provides a rapid way to
reconvert this acetate to acetyl-CoA
for use in reacetylating histones and
thereby maintaining the epigenetic
code. Although ACSS2 is not essential
for this function in normal tissues, as evi-
denced by the viable ACSS2 knockout1494 Cell 159, December 18, 2014 ª2014 Elsmouse, it is possible that certain cancer
cells require this function to maintain
gene expression profiles optimized for
rapid growth. Exogenous acetate, in
this case, is treated equivalently to that
generated by deacetylation. Regardless
of the mechanism(s) by which cancer
cells utilize acetate, the insights provided
by these studies position acetate meta-
bolism as a potentially exploitable vulner-
ability in cancer metabolism.ACKNOWLEDGMENTS
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Functional recovery can occur after incomplete spinal cord injury. Takeoka et al. now report that
such recovery relies on muscle spindle feedback that is necessary for neuronal circuit remodeling,
suggesting novel targets to restore motor functions following spinal cord injuries.Following incomplete lesions of the spinal
cord, substantial recovery of sensory mo-
tor functions is observed (Curt et al., 2008;
Martinez et al., 2012). Previous work has
shown that such a recovery correlates
with the formation of intraspinal circuits
that bypass the injury (Bareyre et al.,
2004; Courtine et al., 2008). Although
sensory afferents are known to play a
key role in the recovery process (Helgren
and Goldberger, 1993), the sensory mo-
dality that allows the injured nervoussystem to re-establish functional connec-
tions has remained elusive. In this
issue, Takeoka et al. (2014) provide evi-
dence for the role of muscle spindle
feedback in promoting neuroplasticity
and motor recovery following spinal cord
injury (SCI).
Muscle spindles are sensory mechano-
receptors specialized for proprioception.
They are located in skeletal muscles,
and consist of several specialized intra-
fusal muscle fibers surrounded by acapsule of connective tissue (Figure 1A).
Muscle spindles are innervated by
specialized motor and sensory axons.
Deformation of intrafusal muscle fibers
generates action potentials by activating
stretch-sensitive ion channels expressed
along the sensory axons that are coiled
around the central part of the spindle.
These axons connect to spinal motor-
neurons and different classes of inter-
neurons that control muscle activity
necessary for accurate body movements.
